This may be due to GC therapy benefiting only a subset of patients whose disease has mainly progressed as a result of an excessive inflammatory response (which can be controlled with GC therapy), rather than a failed reaction to the infection, which was demonstrated for GC-treated TB meningitis patients with specific polymorphisms in the LTA4H gene (32). The gene discussed is LTA4H; the disease is meningitis.